ACADEMIC CONSORTIUM

The ReIMAGINE consortium comprises many of the world’s globally pre-eminent thought leaders in the area of prostate cancer diagnosis (Ahmed, Moore, and Emberton), imaging (Punwani), molecular characterisation (Attard and Whitaker), clinical epidemiology (Van Hemelrijck), advanced analytics (Coolen) and statistics (Brown), and global consortia/consensus development (Moore).

PROFESSOR MARK EMBERTON

​

Professor of Interventional Oncology at UCL. Mark will lead WS7, project management/commercial. Project Management (PM) will be informed at every stage by real-time inputs.All work strands will be advanced & coordinated by means of our PM system that will also serve our numerous commercial partners.

PROFESSOR HASHIM AHMED

 

Academic urologist with an interest in improving diagnosis and treatment options for men with prostate cancer through translational studies, health technology assessment and clinical trials.

PROFESSOR SHONIT PUNWANI

 

Professor of Magnetic Resonance and Cancer Imaging  and Consultant Radiologist at UCLH Shonit will lead on WS3. Curation and post-processing of the imaging (MRI) data will be managed through WS3.

PROFESSOR GERHARDT ATTARD

​

A John Black Charitable Foundation Endowed Chair in Urological Cancer Research at University College London. Gert will lead WS4. Genomic, transcriptomic, epigenetic, immune/inflammatory data from tumour cores, blood and urine will be manged through WS4.

Dr MIEKE VAN HEMELRIJCK

 

Reader in Cancer Epidemiology at KCL, is leading the database management of the ReIMAGINE Consortium as well as the patient and public involvement. Mieke is an expert in clinical epidemiology, specifically in the context of big data for urological cancers.

PROFESSOR ANTHONY COOLEN

​

Applied mathematician with an interest in the development and application of
advanced mathematical and statistical methods for predicting cancer outcomes and treatment response from complex data. 

PROFESSOR CAROLINE MOORE

 

Professor of Urology at UCL is leading the screening study of ReIMAGINE seeking to determine the utility of MRI in men, identified via their GP practice,  who have never had a PSA test. Caroline is working with experts in cancer screening and imaging in ReIMAGINE. 

DR HALEY WHITAKER

 

Reader in Cancer Biology at UCL, with expertise in prostate cancer biomarker development and validation

DR LOUISE BROWN

​

A Senior Statistician at the MRC Clinical Trials Unit at University College London, who will be working on the statistical aspects of REIMAGINE.

STEVE TUCK

​

A prostate cancer survivor -  his role is to work with fellow men diagnosed with prostate cancer and relatives to ensure that the patient is at the centre of the study.